All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
BMT CTN 1703 post hoc analysis: PTCy-based GvHD prophylaxis in older patients
Bookmark this article
|
A post hoc analysis of the BMT CTN 1703 trial (NCT03959241) evaluated the impact of PTCy/ Tac/ MMF vs Tac/MTX in GvHD prophylaxis in patients aged ≥70 years undergoing allo-HSCT from an HLA-matched donor (n = 96 randomized, n = 94 received transplant).1 Results were presented by Abedin at the 66th ASH Annual Meeting and Exposition.1 The primary endpoint was 1-year GFRS and secondary endpoints included GFS, TRM, and OS.1 |
| Key learnings |
| GvHD prophylaxis with PTCy/Tac/MMF was superior to Tac/MTX, resulting in higher GRFS (63.1% vs 29.9%; HR, 0.341; p < 0.001) and improved OS (90.6% vs 61.8%; HR, 0.186; p = 0.003). |
| Higher rates of GFS (72.4% vs 41.3%, p = 0.001) and systemic ISFS (60.0% vs 38.8%, p = 0.046) were seen in the PTCy/Tac/MMF vs Tac/MTX group. |
| Lower incidence of Grade 3 aGvHD and cGvHD were seen in the PTCy/Tac/MMF vs Tac/MTX group (0.0% vs 9.9%; p = 0.175 and 18.3% vs 24.4%; p = 0.089, respectively); 1-year TRM was also lower (4.6% vs 20.0%, p = 0.038). |
| PTCy-based GvHD prophylaxis improved GvHD control without increasing toxicity in older patients undergoing transplant. Future efforts aimed at reducing PTCy-related toxicity may help improve access to allo-HSCT in this population. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; aGvHD, acute graft-versus-host disease; ASH, American Society of Hematology; BMT CTN, Blood and Marrow Transplant Clinical Trial Network; cGvHD, chronic graft-versus-host disease; GFS, graft-failure-free survival; GRFS, graft-versus-host disease-free relapse-free survival; HLA, human leukocyte antigen, ISFS, immunosuppressive free-survival; MMF, mycophenolate mofetil; MTX, methotrexate; OS, overall survival; PTCy, post-transplant cyclophosphamide; TRM, treatment-related mortality; Tac, tacrolimus.
- Abedin S. Oral abstract #1042. Superiority of post-transplant cyclophosphamide-based graft versus host disease (GvHD) prophylaxis in patients 70 years and older: A BMT CTN 1703 post-hoc analysis. 66th American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 9, 2024; San Diego, US.
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox